Back to Search
Start Over
[Gastroesophageal reflux disease in 2024].
- Source :
-
Revue medicale suisse [Rev Med Suisse] 2024 Aug 28; Vol. 20 (884), pp. 1464-1468. - Publication Year :
- 2024
-
Abstract
- Gastroesophageal reflux disease is the most frequent gastroente-rological diagnosis, with a high prevalence of symptoms impacting patients' quality of life and causing high economic costs. It has a -complex pathophysiology that encompasses different mechanisms and an overlap with functional disorders that cause similar symptoms. Hence, an accurate diagnosis and phenotyping of patients is crucial to individualize therapy and limit health costs. Nowadays, therapy is personalized and encompasses lifestyle interventions, proton pump inhibitors, surgery, neuromodulation, diaphragmatic breathing as well as, in the future, new drugs and endoscopic interventions.<br />Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
Details
- Language :
- French
- ISSN :
- 1660-9379
- Volume :
- 20
- Issue :
- 884
- Database :
- MEDLINE
- Journal :
- Revue medicale suisse
- Publication Type :
- Academic Journal
- Accession number :
- 39219387
- Full Text :
- https://doi.org/10.53738/REVMED.2024.20.884.1464